International oncologist to explore why biosimilars make sense
UK oncologist Dr Paul Cornes will address the APP audience on the economic and therapeutic benefits of biosimiliar medicines.
Paul has a special interest in delivering cost-effective care in middle income and high-middle income countries and was recently part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment.
Following his presentation, Paul will be available at the GBMA Education stand (#28–29) during the morning tea, lunch and afternoon tea breaks to personally discuss his international experience with biosimilar medicines.
The GBMA is a representative body of generic and biosimilar medicine suppliers in Australia. Its members offer high-quality generic and biosimilar medicines, whilst providing affordable community health outcomes that benefit all Australians.
Date: Saturday 5 May
Time: 8.30am – 9.30am
View the full program here.
Proudly sponsored by